172 related articles for article (PubMed ID: 37635172)
21. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.
Dao T; Yan S; Veomett N; Pankov D; Zhou L; Korontsvit T; Scott A; Whitten J; Maslak P; Casey E; Tan T; Liu H; Zakhaleva V; Curcio M; Doubrovina E; O'Reilly RJ; Liu C; Scheinberg DA
Sci Transl Med; 2013 Mar; 5(176):176ra33. PubMed ID: 23486779
[TBL] [Abstract][Full Text] [Related]
22. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
[TBL] [Abstract][Full Text] [Related]
23. Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers.
Walseng E; Wang B; Yang C; Patel P; Zhao C; Zhang H; Zhao P; Mazor Y
Front Immunol; 2023; 14():1275304. PubMed ID: 38022650
[TBL] [Abstract][Full Text] [Related]
24. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
25. The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.
Shen Y; Li YM; Zhou JJ; Zhou Z; Xu YC; Zhao WB; Chen SQ
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31408937
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
27. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
[TBL] [Abstract][Full Text] [Related]
28. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.
Akahori Y; Wang L; Yoneyama M; Seo N; Okumura S; Miyahara Y; Amaishi Y; Okamoto S; Mineno J; Ikeda H; Maki T; Fujiwara H; Akatsuka Y; Kato T; Shiku H
Blood; 2018 Sep; 132(11):1134-1145. PubMed ID: 30045840
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
31. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
Front Immunol; 2021; 12():663379. PubMed ID: 33936101
[TBL] [Abstract][Full Text] [Related]
32. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
Dao T; Xiong G; Mun SS; Meyerberg J; Korontsvit T; Xiang J; Cui Z; Chang AY; Jarvis C; Cai W; Luo H; Pierson A; Daniyan A; Yoo S; Takao S; Kharas M; Kentsis A; Liu C; Scheinberg DA
Blood; 2024 Feb; 143(6):507-521. PubMed ID: 38048594
[TBL] [Abstract][Full Text] [Related]
33. The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.
Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
Med Oncol; 2022 Sep; 39(12):232. PubMed ID: 36175774
[TBL] [Abstract][Full Text] [Related]
34. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract][Full Text] [Related]
35. Structural basis for antibody recognition of the proximal MUC16 ectodomain.
Lee K; Perry K; Xu M; Veillard I; Kumar R; Rao TD; Rueda BR; Spriggs DR; Yeku OO
J Ovarian Res; 2024 Feb; 17(1):41. PubMed ID: 38374055
[TBL] [Abstract][Full Text] [Related]
36. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
[TBL] [Abstract][Full Text] [Related]
38. Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.
Ataie N; Xiang J; Cheng N; Brea EJ; Lu W; Scheinberg DA; Liu C; Ng HL
J Mol Biol; 2016 Jan; 428(1):194-205. PubMed ID: 26688548
[TBL] [Abstract][Full Text] [Related]
39. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
[TBL] [Abstract][Full Text] [Related]
40. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
